SCHEMBL2125665

SCHEMBL2125665

COc1cc(-c2[nH]c3c(C#N)cnn3c2Nc2ccc(SC)c(F)c2)cc(OC)c1OC

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A1 P68400 1/20 0.35
▸ EGFR P00533 7/20 0.34
▸ PRKCQ Q04759 4/20 0.34
▸ ERBB2 P04626 3/20 0.34
▸ MAP2K1 Q02750 1/20 0.33
▸ GAK O14976 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ ADORA2A P29274 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ PTK2 Q05397 1/20 0.32
▸ SLK Q9H2G2 1/20 0.32
▸ PRKCH P24723 1/20 0.32
▸ PRKCE Q02156 1/20 0.32
▸ PRKCD Q05655 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2125204 0.90 CSNK2A1 (0.40) CSNK2A1EGFRPRKCQERBB2GAK
SCHEMBL2126571 0.90 CSNK2A1 (0.38) CSNK2A1EGFRPRKCQERBB2GAK
SCHEMBL2128281 0.88 CSNK2A1 (0.37) CSNK2A1EGFRPRKCQERBB2GAK
SCHEMBL2122015 0.88 CSNK2A1 (0.40) CSNK2A1EGFRPRKCQERBB2GAK
SCHEMBL2125399 0.87 SRC (0.39) CSNK2A1EGFRGAKSRCADORA2A
SCHEMBL2123771 0.86 LMNA (0.40) CSNK2A1EGFRPRKCQERBB2GAK
SCHEMBL2123111 0.86 CSNK2A1 (0.47) CSNK2A1EGFRPRKCQERBB2GAK
SCHEMBL2124510 0.86 EGFR (0.49) CSNK2A1EGFRPRKCQERBB2GAK
SCHEMBL2124727 0.85 SRC (0.44) CSNK2A1EGFRPRKCQGAKSRC
SCHEMBL2125879 0.84 TNIK (0.40) CSNK2A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP claimed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US claimed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US claimed
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-20150216955-A1 IMMUNOMODULATORY AGENT AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2015-08-06 — — US disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150216955-A1 IMMUNOMODULATORY AGENT AND USES THEREFOR HLA-DRB1, CD74, CHI3L1 CSNK2A1 4410/4885EGFR 4464/4885PRKCQ 3208/4885
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK CSNK2A1 489/4885EGFR 1784/4885PRKCQ 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback